Results 221 to 230 of about 14,885 (290)
Biophysical basis of tight junction barrier modulation by a pan-claudin-binding molecule. [PDF]
Ogbu CP +12 more
europepmc +1 more source
The current obesity drug landscape, dominated by GLP‐1 receptor agonists and emerging multi‐agonist therapies, has reinforced that long‐term weight loss is achieved in large part through central mechanisms that suppress appetite and reshape energy balance.
Ines Martinez‐Corral +3 more
wiley +1 more source
KRTAP2‐3 drives OSCC progression by sustaining both mesenchymal and proliferative properties through KRAS signaling. Loss of KRTAP2‐3 induces MET, suppresses KRAS pathway activation, and markedly reduces tumor cell proiferation and tumor formation as illustarted in Figure.
Qianqian Miao +6 more
wiley +1 more source
Adaptive epithelial-mesenchymal bi-directional transition: A key invasive plasticity for tumor metastasis. [PDF]
Liu Y +11 more
europepmc +1 more source
Lung cancer brain metastasis is shaped by dynamic crosstalk among tumor cells, the blood–brain barrier, glial and immune cells, neurons, and metabolic niches. This review integrates these mechanisms with therapeutic resistance, translational models, CNS delivery, and multidisciplinary treatment strategies.
Jun Yang +6 more
wiley +1 more source
The Intestinal Barrier: A Multilayered Gatekeeper Against Systemic Disease. [PDF]
Wakabayashi J, Kimura K, Kawauchi T.
europepmc +1 more source
Differential Expression of Claudin-3 and Claudin-1 in Mycosis Fungoides: Implications for Disease Monitoring. [PDF]
Aktaş A +4 more
europepmc +1 more source
ABSTRACT Aims Diabetic kidney disease (DKD) is one of the main causes of kidney failure worldwide. Interestingly, patients affected by DKD are characterised by a low abundance of gut bacteria producing short fatty acids including butyrate, which is suggested to play a role in the decline of renal function.
Maria Novella Nicese +13 more
wiley +1 more source
Gut-liver-hypothalamus axis dysfunction in mycotoxin toxicity: mechanisms and protective roles of natural compounds. [PDF]
Ennab W +7 more
europepmc +1 more source
Effects of GLP‐1 agonists on the gut microbiota in type 2 diabetes mellitus: a systematic review
This systematic review evaluated 17 studies (12 preclinical and five clinical) on GLP‐1 receptor agonists in type 2 diabetes, demonstrating effects on the gut microbiota and metabolic improvement. The studies showed an increase in Bacteroidetes, Lactobacillus, and Akkermansia, and a reduction in Firmicutes.
Ranicleide Santos Dantas +11 more
wiley +1 more source

